Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

NCT04072887 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

974

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: QBW251
DRUG: Placebo
DRUG: COPD maintenance background therapy

Sponsor

Novartis Pharmaceuticals